c'è chi c'ha e chi non c'ha

Quanto quoteremo a fine mese in USA?


  • Votanti
    48
io ho impostato un ordine di vendita a 0,6250 della durata di un mese...speriamo che venga eseguito :bye:
 
Abnormally Low Company Efficiency Detected in Shares of Cell Therapeutics in the Biotechnology Industry (CTIC, DNDN, TTNP, OREX, PLX)
Written on Thu, 04/15/2010 - 20:28
By Chip Brian
Below are the top five most inefficient companies in the Biotechnology industry as ranked by Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.
Cell Therapeutics (NASDAQ:CTIC) ranks first with an RPE of $0K; Dendreon (NASDAQ:DNDN) ranks second with an RPE of $1K; and Titan Pharmaceuticals (NASDAQ:TTNP) ranks third with an RPE of $2K.
Orexigen Therapeutics (NASDAQ:OREX) follows with an RPE of $2K and Protalix BioTherapeutics (AMEX:PLX) rounds out the top five with an RPE of $3K.
SmarTrend is bullish on shares of DNDN and our subscribers were alerted to Buy on March 13, 2009 at $3.84. The stock has risen 933.1% since the alert was issued.
 
buongiorno a tutti, toccata e fuga...vado di fretta....
 
...ce ne sono due aperti .....quale seguiamo? :mmmm:
 
Indietro